Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Buy Dr Lal Pathlabs; target of Rs 1740: Emkay Global Financial
Emkay Global Financial is bullish on Dr Lal Pathlabs has recommended buy rating on the stock with a target price of Rs 1740 in its research report dated Jun 09, 2026.
Reduce Cyient; target of Rs 900: Emkay Global Financial
Emkay Global Financial recommended reduce rating on Cyient with a target price of Rs 900 in its research report dated Jun 15, 2026.
Buy Pine Labs; target of Rs 225: Emkay Global Financial
Emkay Global Financial is bullish on Pine Labs has recommended buy rating on the stock with a target price of Rs 225 in its research report dated Jun 17, 2026.
Buy Coforge; target of Rs 1550: Emkay Global Financial
Emkay Global Financial is bullish on Coforge has recommended buy rating on the stock with a target price of Rs 1550 in its research report dated Jun 17, 2026.
Buy Park Medi World; target of Rs 350: Emkay Global Financial
Emkay Global Financial is bullish on Park Medi World has recommended buy rating on the stock with a target price of Rs 350 in its research report dated Jun 18, 2026.
Buy Sobha; target of Rs 1900: Emkay Global Financial
Emkay Global Financial is bullish on Sobha has recommended buy rating on the stock with a target price of Rs 1900 in its research report dated Jun 18, 2026.
Buy Timken India; target of Rs 4207: Emkay Global Financial
Emkay Global Financial is bullish on Timken India has recommended buy rating on the stock with a target price of Rs 4207 in its research report dated Jun 19, 2026.
Buy Tata Motors; target of Rs 600: Emkay Global Financial
Emkay Global Financial is bullish on Tata Motors has recommended buy rating on the stock with a target price of Rs 600 in its research report dated Jun 23, 2026.
Nifty at 29,000 by March 2027? Emkay's Seshadri Sen Shares Top Stock Picks
Can the Nifty hit 29,000 by March 2027? In this conversation with Surabhi Upadhyay, Emkay Global's Head of Research & Strategist Seshadri Sen explains why falling oil prices, a stronger rupee, improving earnings growth and resilient domestic flows could drive a 20% rally in Indian equities. He also shares his favourite sectors, key risks to watch and top investment themes for the next two years.
Vijaya Diagnostic gains over 3% as Emkay reiterates buy, sees strong growth across key markets
The stock climbed as much as 5 percent to an intraday high of Rs 1,375.30 before trading at Rs 1,358.80, up 3.5 percent, in afternoon trade
Buy Vijaya Diagnostic; target of Rs 1400: Emkay Global Financial
Emkay Global Financial is bullish on Vijaya Diagnostic has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated Jun 24, 2026.